Search

In this study, we determined the effect of TNF-α on hBMSCs proliferation as well as the role of IL-1 receptor-associated kinase 1 (IRAK1) on TNF-α signaling. Western blot analysis revealed that TNF-α treatment increased the phosphorylation of IRAK1 in hBMSCs. The downregulation of IRAK1 inhibited TNF-α-induced NF-ĸB activation and COX-2 expression. TNF-α treatment increased hBMSCs proliferation in a dose-dependent manner and increased ERK, JNK, and NF-ĸB activity. U0126, an ERK inhibitor, decreased hBMSCs proliferation and significantly blocked TNF-α -induced hBMSCs proliferation. In cells with IRAK1 or TRADD downregulation, the U0126 treatment inhibited hBMSCs proliferation and significantly suppressed TNF-α-induced hBMSCs proliferation. The downregulation of IRAK1 or TRADD inhibited TNF-α-induced ERK and JNK activation, and hBMSCs proliferation. Inhibition of NF-ĸB by decoy oligonucleotides reduced the TNF-α-induced hBMSCs proliferation. Immunoprecipitation analysis showed that IRAK1 does not physically interact with TNF receptor 1 (TNFR1) even in the presence of TNF-α. Suppression of IRAK1 binding protein (IRAK1BP1) inhibited TNF-α-induced increase of the proliferation and ERK1 phosphorylation of hBMSCs in the presence of TNF-α. Our data indicate that TNF-α modulates hBMSCs proliferation through ERK signaling pathways, and that IRAK1 plays an important role in TNF-α-induced NF-ĸB activation in hBMSCs.

Human bone marrow stromal cells (hBMSCs) are defined as pluripotent progenitor cells with the ability to differentiate into osteoblasts, chondrochytes, adipocytes, muscle cells, and neural cells. Recently, it has been shown that telomerase expression not only extends the replicative life-span and maintains their bone-forming capability of hBMSCs. We previously reported that human adipose tissue stromal cells (hATSCs) have similar characteristics with hBMSCs. In this study, hATSCs were stably tranduced by a retrovirus containing the gene for the catalytic subunit of human telomerase (hTERT) and MSCV-neo retrovirus, and 12 clones for hTERT-hATSCs and 6 clones for MSCV-hATSCs were isolated. The tranduced clones (hATSC-TERTs) had high telomerase activity, which was maintained during subsequent subcultivation. The transduced cells of two representative clones have undergone more than 100 population doublings (PD) and continue to proliferate, whereas control cells underwent senescence-associated proliferation arrest after 36-40 PD. The cells had a normal karyotype, and increased differentiation potential, especially osteogenic lineage. Intraventricular injection of hATSC-TERTs in ischemic rat brain showed enhancement of functional recovery as like hATSC-MSCVs. The tissue engraftment of hATSCs and hTERT-hATSCs in NOD/SCID mice after intravenous administration was identical. These results further support a similarity between hBMSCs and hATSCs. hATSCs can be used as an alternative of pluripotent stromal cells for cell replacement therapy as like hBMSCs.